FTSE MIB
34.167,57 -74,92 (-0,22%) Dow Jones
38.884,26 +31,99 (+0,08%) Nasdaq
16.332,56 -16,69 (-0,10%) Nikkei 225
38.202,37 -632,73 (-1,63%) Petrolio
77,65 -0,73 (-0,93%) Bitcoin EUR
57.862,53 -1.763,45 (-2,96%)
Verona Pharma plc (VRNA)
Dopo ore:
| Chiusura precedente | 14,95 |
| Aperto | 15,15 |
| Denaro | 14,76 x 400 |
| Lettera | 14,86 x 100 |
| Min-Max giorno | 14,60 - 15,15 |
| Intervallo di 52 settimane | 11,83 - 23,81 |
| Volume | |
| Media Volume | 444.960 |
| Capitalizzazione | 1,145B |
| Beta (5 anni mensile) | 0,41 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,72 |
| Prossima data utili | 09 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 34,29 |
GlobeNewswireVerona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023
LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold an Investor Update in New York City for investors and analysts on Wednesday, October 18, 2023, from 8:00 - 10:00 AM ET. Members of Verona’s senior management team will be joined by key opinion leader Cedric “Jamie” Rutland, MD, FCCP, Medical Director & CEO of West Coast Lung, to discuss the COPD treatment paradigm and the Company’s preparations f
- GlobeNewswire
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces four presentations on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”)
- GlobeNewswire
Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD
PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade LONDON and RALEIGH, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the US Food and Drug Administration (“FDA”) has accepted for review the Company’s New Drug Application (“NDA”) seeking approval of ensifentrine for the maintenance treatment of
